{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:13:13Z","timestamp":1783750393833,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01637-1","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:44:21Z","timestamp":1779806661000},"page":"1061-1072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients \u2265 3 to &lt; 18 Years of Age with Genotypes 1\u20136 Chronic Hepatitis C Virus (HCV) Infection"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-8676","authenticated-orcid":false,"given":"Neha","family":"Thakre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-6988","authenticated-orcid":false,"given":"Denise","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3907-7921","authenticated-orcid":false,"given":"Ahmed M.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5946-2364","authenticated-orcid":false,"given":"Doerthe","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mong-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-1230","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-3144","authenticated-orcid":false,"given":"Hoi Kei","family":"Lon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-768X","authenticated-orcid":false,"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-647X","authenticated-orcid":false,"given":"Sven","family":"Mensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"1637_CR1","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. World Health Organization; 2016. https:\/\/iris.who.int\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf;jsessionid=0C19EC64015F8BAF508A13427DB21BFB?sequence=1. Accessed 20 Aug 2024."},{"issue":"8","key":"1637_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","volume":"19","author":"MP Manns","year":"2022","unstructured":"Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;19(8):533\u201350. https:\/\/doi.org\/10.1038\/s41575-022-00608-8.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"1637_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/MPG.0000000000002710","volume":"70","author":"G Indolfi","year":"2020","unstructured":"Indolfi G, Fischler B, Gonzalez-Peralta RP, Ciocca M, Porta G, Neelam M, et al. Comparison of recommendations for treatment of chronic Hepatitis C Virus infection in children and adolescents: a position paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2020;70(5):711\u20137. https:\/\/doi.org\/10.1097\/MPG.0000000000002710.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"1637_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/liv.15827","volume":"44","author":"G Indolfi","year":"2024","unstructured":"Indolfi G, Easterbrook P, Giometto S, Malik F, Chou R, Lucenteforte E. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: a systematic review and meta-analysis. Liver Int. 2024;44(3):663\u201381. https:\/\/doi.org\/10.1111\/liv.15827.","journal-title":"Liver Int"},{"issue":"2","key":"1637_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12519-022-00612-7","volume":"19","author":"V Venkatesh","year":"2023","unstructured":"Venkatesh V, Seetharaman K, Anushree N. Treatment of Hepatitis C in children and adolescents: how far have we reached? World J Pediatr. 2023;19(2):107\u201319. https:\/\/doi.org\/10.1007\/s12519-022-00612-7.","journal-title":"World J Pediatr"},{"issue":"2","key":"1637_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5223\/pghn.2016.19.2.83","volume":"19","author":"MA El-Guindi","year":"2016","unstructured":"El-Guindi MA. Hepatitis C viral infection in children: updated review. Pediatr Gastroenterol Hepatol Nutr. 2016;19(2):83\u201395. https:\/\/doi.org\/10.5223\/pghn.2016.19.2.83.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"6","key":"1637_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.pcl.2021.07.008","volume":"68","author":"SR Yadav","year":"2021","unstructured":"Yadav SR, Goldman DA, Murray KF. Hepatitis C: current state of treatment in children. Pediatr Clin North Am. 2021;68(6):1321\u201331. https:\/\/doi.org\/10.1016\/j.pcl.2021.07.008.","journal-title":"Pediatr Clin North Am"},{"issue":"9","key":"1637_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for Hepatitis C Virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348. https:\/\/doi.org\/10.7326\/M16-2575.","journal-title":"Ann Intern Med"},{"key":"1637_CR9","unstructured":"Mavyret\u2122 (glecaprevir and pibrentasvir) [package insert]. North Chicago, IL. USA. Abbvie Inc. Revised October 2023."},{"key":"1637_CR10","unstructured":"Maviret (glecaprevir\/pibrentasvir) [EU summary of product characteristics]. Ludwigshafen, Germany; AbbVie Deutschland GmbH & Co. KG, 2019."},{"issue":"10","key":"1637_CR11","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic Hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(17)30496-6.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"1637_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","volume":"5","author":"L Wei","year":"2020","unstructured":"Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, et al. Glecaprevir-pibrentasvir to treat chronic Hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol. 2020;5(9):839\u201349. https:\/\/doi.org\/10.1016\/S2468-1253(20)30086-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1637_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.30840","volume":"71","author":"MM Jonas","year":"2020","unstructured":"Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C, et al. Pharmacokinetics, safety, and efficacy of Glecaprevir\/Pibrentasvir in adolescents with chronic Hepatitis C Virus: Part 1 of the DORA Study. Hepatology. 2020;71(2):456\u201362. https:\/\/doi.org\/10.1002\/hep.30840.","journal-title":"Hepatology"},{"issue":"1","key":"1637_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31841","volume":"74","author":"MM Jonas","year":"2021","unstructured":"Jonas MM, Rhee S, Kelly DA, Del Valle-Segarra A, Feiterna-Sperling C, Gilmour S, et al. Pharmacokinetics, safety, and efficacy of Glecaprevir\/Pibrentasvir in children with chronic HCV: Part 2 of the DORA Study. Hepatology. 2021;74(1):19\u201327. https:\/\/doi.org\/10.1002\/hep.31841.","journal-title":"Hepatology"},{"issue":"3","key":"1637_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jcph.1524","volume":"60","author":"AA Suleiman","year":"2020","unstructured":"Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, et al. Population pharmacokinetics of Glecaprevir\/Pibrentasvir in HCV-infected Japanese subjects in Phase 3 CERTAIN-1 and CERTAIN-2 trials. J Clin Pharmacol. 2020;60(3):331\u20139. https:\/\/doi.org\/10.1002\/jcph.1524.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1637_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13318-017-0428-8","volume":"43","author":"CW Lin","year":"2018","unstructured":"Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu W. Pharmacokinetic interactions and safety of coadministration of Glecaprevir and Pibrentasvir in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2018;43(1):81\u201390. https:\/\/doi.org\/10.1007\/s13318-017-0428-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"1637_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.xphs.2016.10.007","volume":"106","author":"CW Lin","year":"2017","unstructured":"Lin CW, Dutta S, Asatryan A, Chiu YL, Wang H, Clifton J 2nd, et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study. J Pharm Sci. 2017;106(2):645\u201351. https:\/\/doi.org\/10.1016\/j.xphs.2016.10.007.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1637_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpdd.350","volume":"7","author":"CW Lin","year":"2018","unstructured":"Lin CW, Dutta S, Asatryan A, Wang H, Clifton J 2nd, Campbell A, et al. Pharmacokinetics, safety, and tolerability following single and multiple doses of Pibrentasvir in a first-in-human study. Clin Pharmacol Drug Dev. 2018;7(1):44\u201352. https:\/\/doi.org\/10.1002\/cpdd.350.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"1637_CR19","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/hep.30123","volume":"68","author":"KF Murray","year":"2018","unstructured":"Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, et al. Safety and efficacy of Ledipasvir-Sofosbuvir with or without Ribavirin for chronic Hepatitis C in children ages 6-11. Hepatology. 2018;68(6):2158\u201366. https:\/\/doi.org\/10.1002\/hep.30123.","journal-title":"Hepatology"},{"key":"1637_CR20","doi-asserted-by":"crossref","unstructured":"Jonas MM, Romero R, Sokal EM, et al. Safety and efficacy of sofosbuvir\/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection [abstract 748]. The Liver Meeting. Boston, Massachusetts; 2019.","DOI":"10.1136\/gutjnl-2020-IDDF.142"},{"issue":"5","key":"1637_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11598930-000000000-00000","volume":"51","author":"SC McLeay","year":"2012","unstructured":"McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319\u201330. https:\/\/doi.org\/10.2165\/11598930-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1637_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"issue":"5","key":"1637_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01637-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:56Z","timestamp":1783748216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01637-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01637-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Denise Beck, Doerthe Eckert, Mong-Jen Chen, Nael Mostafa, Sven Mensing, and Wei Liu are employees of AbbVie and may hold AbbVie stock, stock options, and\/or patents. Neha Thakre, Ahmed Saeed, and Hoi Kei Lon are former employees of AbbVie Inc. and may hold stock, stock options, and\/or patents in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in these studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All participants provided written consent prior to participation or study-related procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All individual participants signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this article for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or on submitting a request, visit the following link:\n                      \n                      , then select \u201cHome.\u201d","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Neha Thakre, Denise Beck, Ahmed M. Saeed, Doerthe Eckert, Hoi Kei Lon, and Sven Mensing. The first draft of the manuscript was written by Neha Thakre\u00a0and Denise Beck, and all authors were involved in revising it critically for important intellectual content. All authors approved the final manuscript for publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}